Terumo Corporation · TSE:4543
Terumo — Merger or Acquisition (August 2025)
13 slides from Terumo's merger presentation, Aug 27, 2025
Slide 1: Acquisition of OrganOx
Acquisition of OrganOx ~Expanding transplant opportunities for waiting patients globally and contributing to the development of transplant medicine~ Terumo Corporation Chief Executive Officer Hikaru Samejima August 27, 2025
Slide 2: Acquisition Overview
Acquisition Overview Target Company OrganOx Limited Acquisition Price $1.5B（cash free / debt free basis） Transaction Acquisition of 100% of OrganOx's outstanding shares in cash consideration Structure August 23, 2025 Signing Date *Closing is scheduled to be completed by the end of FY2025. Acquisitio
Slide 3: OrganOx Overview
OrganOx Overview About OrganOx OrganOx's History 1997 Core technology was developed at Oxford University • Year of Establishment: 2008 • Head Office: Oxford, UK 2008 As a spin-off from Oxford University • Number of employees: 199 (as of June 30, 2025) OrganOx was established • Revenue: $71M (2024) 2
Slide 4: Strategic Rationale of the Acquisition
Strategic Rationale of the Acquisition Driving portfolio enhancement & accelerated growth through a bold add-on Addressing the significant unmet needs in shortage of transplant organs Entering high-growth industry and acquiring high- profitability business Enhancing corporate value by creating solut
Slide 5: Current Situation of Organ Transplantation
Current Situation of Organ Transplantation Supply cannot keep up with demand, resulting in many lives lost during the waiting period Number of organ transplants worldwide: more than 150,000 per year The waiting list (470,000 patients) is the tip of the iceberg, and it is estimated that the actual nu
Slide 6: Challenges of Liver Transplantation
Challenges of Liver Transplantation Due to the challenges of liver preservation and function evaluation, the number of donors and utilization rate are limited • Number of donors: Utilization of cardiac arrest donors has not progressed, resulting in a limited donor pool • Utilization rate: 37%* of tr
Slide 7: OrganOx's Solution
OrganOx's Solution OrganOx’s technology contributes to expand the number of donors and increase the utilization of transplant liver Normothermic Machine Perfusion (NMP) OrganOx Preserving donor organs through Real-time monitoring and automatic control normothermic machine perfusion Preservation is a
Slide 8: Future Pipeline Expansion
Future Pipeline Expansion Alongside the development of next-generation liver devices, targeting entry into the kidney field Next-generation device for liver Kidney transplant device transplantation metra L metra K • Downsizing the current metra • Like metra for the liver, it will have • Reduces tran
Slide 9: High-growth and High-profitability Model
High-growth and High-profitability Model Positioned to become a leader in a growing industry, while also achieving adjusted EBITDA profitability just one year after the U.S. launch Sales (100 million yen*) 1000 400 350 ・・・ 300 250 200 200 150 107 100 47 50 18 0 0 CY In 2022 In 2023 2024 2025 ・・・ 203
Slide 10: Financial Impact of the Acquisition
Financial Impact of the Acquisition • Adjusted operating profit contributes positively Operating Profit (Excluding amortization of intangible assets and one-time costs in acquisitions) Impact • Details of goodwill, intangible fixed assets, etc. will be disclosed once finalized • EPS before amortizat
Slide 11: Synergy with the Terumo Group
Synergy with the Terumo Group Combining OrganOx's products with assets from all Terumo Group companies to create synergies Technology cultivated over 100 years and a wide range of lineups Perfusion Coating Organ Perfusion Solution Organ Infusion Non-clinical Robust R&D transplantation Management Eva
Slide 12: Achieving Accelerated Growth
Achieving Accelerated Growth By acquiring innovative technologies addressing medical challenges, Terumo drives additional value creation Addressing Enhancing Synergy Unmet Needs Corporate Value Solution Creation Perfusion technology to enhance organ Reducing organ discards and persistence/ Acquiring
Slide 13: ~“TERUMO
~“TERUMO